US$ 21.95
glp-1/gip/glucagon receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Discovery of a potent and
Description
One theory is that they may play a role in osteoblast and osteoclast activity

In November 2023, tirzepatide was also approved for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity

All studies have the percent change from randomization in body weight as the primary endpoint (8285)

58: 28512862 [DOI] [PMC free article] [PubMed] [Google Scholar] 92.Tsunekawa S, Yamamoto N, Tsukamoto K, et al

Diabetes 1999
